1. Introduction {#sec1-jcm-08-00119}
===============

Peak oxygen uptake (VO~2peak~) is an important metric for cardiac transplantation (HTx) eligibility. The measurement of exercise capacity using VO~2peak~ obtained from cardiopulmonary exercise testing (CPET) is one criteria used for determination of transplant eligibility; with a value of ≤14 mL/kg/min considered transplant eligible \[[@B1-jcm-08-00119],[@B2-jcm-08-00119],[@B3-jcm-08-00119],[@B4-jcm-08-00119],[@B5-jcm-08-00119]\]. The association between higher VO~2peak~ and reduced hospitalizations and mortality risk has been shown in both the heart failure (HF) and HTx population, with even modest improvements in VO~2peak~ associated with improved outcomes \[[@B6-jcm-08-00119],[@B7-jcm-08-00119],[@B8-jcm-08-00119],[@B9-jcm-08-00119]\]. Because of this, investigating demographic and clinical factors that are predictive of post-HTx VO~2peak~ has significant implications not only for functional capacity but also long-term survival.

Previous studies have investigated demographic and clinical determinants of VO~2peak~ in various populations \[[@B10-jcm-08-00119],[@B11-jcm-08-00119],[@B12-jcm-08-00119],[@B13-jcm-08-00119],[@B14-jcm-08-00119],[@B15-jcm-08-00119],[@B16-jcm-08-00119],[@B17-jcm-08-00119],[@B18-jcm-08-00119]\]. For example, the predictive influence of age, sex, and body mass index (BMI) on VO~2peak~ has been shown in healthy populations \[[@B16-jcm-08-00119],[@B17-jcm-08-00119]\]. In HTx patients, these variables have also been shown to be prominent predictors of post-HTx VO~2peak~ along with chronotropic reserve, donor age, and time from HTx \[[@B11-jcm-08-00119],[@B13-jcm-08-00119],[@B14-jcm-08-00119],[@B18-jcm-08-00119]\]. However, a limitation of these previous studies is the small sample sizes used (*n* = 60--95) \[[@B11-jcm-08-00119],[@B13-jcm-08-00119],[@B14-jcm-08-00119],[@B18-jcm-08-00119]\]. In addition, recent work has indicated that participation in cardiac rehabilitation (CR) in HTx postoperative care has been shown to be related to improvements in VO~2peak~ \[[@B15-jcm-08-00119],[@B19-jcm-08-00119],[@B20-jcm-08-00119]\]; however, it is unclear if CR participation is predictive of a greater VO~2peak~ following HTx.

Therefore, the purpose of this study was to investigate whether pre-HTx clinical characteristics and/or postoperative CR exercise session attendance provide utility in predicting VO~2peak~ following HTx. Based on previous studies on the relationship between CR involvement and VO~2peak~ \[[@B15-jcm-08-00119],[@B19-jcm-08-00119],[@B20-jcm-08-00119]\], we hypothesize that CR will surpass other predictive factors of post-HTx VO~2peak~ in HTx patients.

2. Experimental Section {#sec2-jcm-08-00119}
=======================

2.1. Participants and Study Design {#sec2dot1-jcm-08-00119}
----------------------------------

A retrospective, single-center study cohort design evaluated consecutive adult HTx patients who performed symptom-limited CPET prior to HTx (pre-HTx) and following HTx (post-HTx) between the years of 2007--2016. Demographic and clinical characteristics were obtained from an institutional database. Inclusion criteria included completion of pre-HTx CPET within 24 months prior to procedural date and post-HTX CPET within 1-year of HTx. Patients were excluded if they lacked CR exercise session data or had incomplete CPET data. Of the 204 HTx patients, 140 were analyzed in this study ([Figure 1](#jcm-08-00119-f001){ref-type="fig"}). This study was approved by the Mayo Clinic Institutional Review Board (IRB \#15-007965) and followed research authorization protocol for the use of medical records as required by the state of Minnesota \[[@B21-jcm-08-00119]\].

2.2. Clinical Characteristics {#sec2dot2-jcm-08-00119}
-----------------------------

Clinical baseline information from the time of HTx procedural date was obtained via medical record extraction. Demographic data along with previous disease history, previous left ventricular assist device (LVAD), current laboratory measurements (i.e., hemoglobin, hematocrit, white blood cell count, and creatinine), indication for HTx (i.e., restrictive cardiomyopathy, dilated cardiomyopathy, hypertrophic cardiomyopathy, ischemic cardiomyopathy, or other), and pre-HTx medication status for the following: angiotensin-converting enzyme (ACE) inhibitor, amiodarone, aspirin, beta blocker, calcium channel blocker, and diuretic were extracted from the procedural sedation assessment at the time of HTx. For the purpose of monitoring data correctness, two investigators independently reviewed a random sampling of medical record charts.

2.3. Cardiac Rehabilitation Participation {#sec2dot3-jcm-08-00119}
-----------------------------------------

Patients included in this study were referred for CR participation and attended at least one documented session following HTx. Medical records were examined to determine CR attendance specifically relating to postoperative HTx care versus CR for any cardiac-related event. As the initial visit for CR typically involves orientation procedures with little to no exercise involvement, this was not assessed in this study. Only those CR sessions with documented exercise participation were included for analysis. All exercise sessions were supervised throughout activity by clinical exercise physiologists with cardiologist oversight. During the course of CR participation patients performed 20--45 min of aerobic activity in a monitored setting, with the usual addition of strength training components for 10--15 min. In addition to CR attendance patients were encouraged to partake in light to moderate physical activity for at least 30 min on all days of the week. Guidance regarding nutrition, medication management, stress management, and depressive symptom management were all components of the comprehensive approach of the CR program. Social support was also provided in this environment as patients all engaged in group education/learning activities throughout CR.

2.4. Cardiopulmonary Exercise Testing Procedures {#sec2dot4-jcm-08-00119}
------------------------------------------------

Clinical exercise physiologists conducted the clinically-indicated CPET with cardiologist oversight. An institutionally designed protocol was performed on a motorized treadmill (GE Case, Milwaukee, WI, USA) with workload increasing every 2 min until volitional fatigue \[[@B22-jcm-08-00119],[@B23-jcm-08-00119]\]. Heart rhythm and heart rate (HR) were continuously monitored via 12-lead electrocardiogram during exercise and recovery. Prior to the start of exercise and at the last 30 s of each stage systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured via manual sphygmomanometry. Flow and gas exchange variables were measured during exercise using indirect calorimetry (MGC Diagnostics, St. Paul, MN, USA). Peak values were obtained by averaging the last 30 s of the CPET data collection. Measured gas exchange variables included VO~2peak~, carbon dioxide production (VCO~2~), minute ventilation (V~E~), and respiratory exchange ratio (RER). The value of V~E~/VCO~2~ slope was determined from rest-peak values for V~E~ and VCO~2~ and %predicted VO~2peak~ \[[@B24-jcm-08-00119]\] was calculated. Peak values were chosen for V~E~/VCO~2~ slope as they have been shown to have superior prognostic value as opposed to the pre-ventilatory threshold slope equation \[[@B25-jcm-08-00119]\]. Patients were monitored closely for development of significant dysrhythmia, electrocardiographic abnormalities, and/or abnormal blood pressure responses (e.g., symptomatic hypotension). Cardiac medications were not withheld prior to CPET to maximize patient safety and generalizability of the data.

2.5. Statistical Analysis {#sec2dot5-jcm-08-00119}
-------------------------

Data are reported as mean ± standard deviation (SD) or frequency (percentage) where applicable. Statistical analysis was conducted using SPSS (version 22.0, Chicago, IL, USA) and JMP (JMP, Cary, NC, USA). The Student's *t* test was used to compare pre-HTx CPET variables to post-HTx CPET variables. As previously described \[[@B26-jcm-08-00119],[@B27-jcm-08-00119]\], univariate binary regression analysis was used to assess individual predictors for the highest post-HTx VO~2peak~ (i.e., quartile 4) based on VO~2peak~ data presented herein. Quartile 4 = VO~2peak~ \> 20.1 mL/kg/min, quartile 3 = VO~2peak~ \> 17.4 mL/kg/min, quartile 2 = VO~2peak~ \> 14.3 mL/kg/min, and quartile 1 = VO~2peak~ ≤ 14.3 mL/kg/min (total range = 24.5 mL/kg/min). A multivariate regression analysis was then performed including all significant univariate variables. Three additional adjustment analyses were conducted to account for potential factors involved in exercise capacity. Model 1 was adjusted for demographic influencers of exercise capacity (i.e., age and sex), Model 2 was adjusted for demographic and clinical influencers of exercise capacity (i.e., age, sex, BMI, history of diabetes, and hemoglobin), and Model 3 included all significant univariate predictors for multivariate analysis adjusted for age and sex. The receiver operating characteristic (ROC) curve model was assessed to establish the area under the curve (AUC) for predicting quartile 4 (i.e., the highest VO~2peak~) and the cut-off for CR for maximal post-HTx VO~2peak~ benefits. Least squares linear regression analysis was performed between pre-HTx VO~2peak~ and post-HTx VO~2peak~, with reporting of the Pearson product-moment correlation coefficient (r) as an indicator of the strength of association between before and after measurements. For all analyses, statistical significance was set at an alpha level of *p* \< 0.05.

3. Results {#sec3-jcm-08-00119}
==========

3.1. Patient Population and Clinical Characteristics {#sec3dot1-jcm-08-00119}
----------------------------------------------------

Demographic and clinical characteristics of the patients included are presented in [Table 1](#jcm-08-00119-t001){ref-type="table"}. Of the 140 HTx patients analyzed in this study the mean age was 52 ± 12 years, mean BMI was 27 ± 5 kg/m^2^, and *n* = 41 (29%) were women. All data shown in [Table 1](#jcm-08-00119-t001){ref-type="table"} was obtained from each patient within 24 months prior to procedural data. The mean number of CR sessions attended was 18 ± 9, with a range of 2--36 sessions.

3.2. Exercise Testing Data Prior to and Following Transplant {#sec3dot2-jcm-08-00119}
------------------------------------------------------------

Peak exercise testing data for CPET pre-HTx versus post-HTx are shown in [Table 2](#jcm-08-00119-t002){ref-type="table"}. All variables included show significant improvements from pre-HTx to post-HTx, with V~E~/VCO~2~ slope decreasing while all other variables increased. Notably, relative VO~2peak~ increased substantially from pre- to post-HTx (12.9 ± 4.4 vs. 17.5 ± 4.6 mL/kg/min, *p* \< 0.001). A significant positive correlation was present between pre-HTx VO~2peak~ and post-HTx VO~2peak~ ([Figure 2](#jcm-08-00119-f002){ref-type="fig"}) (*r* = 0.47, *p* \< 0.01). Additionally, this correlation between pre and post-HTx VO~2peak~ was further analyzed with adjustment for the number of CR exercise sessions attended and remained significant (*p* \< 0.001).

3.3. Predictors of VO~2peak~ {#sec3dot3-jcm-08-00119}
----------------------------

Univariate regression analysis indicated that BMI, history of diabetes, history of dyslipidemia, hemoglobin, white blood cell count, CR exercise sessions, and pre-HTx VO~2peak~ were significant predictors of higher VO~2peak~ post-HTx ([Table 3](#jcm-08-00119-t003){ref-type="table"}). The significance of pre-HTx VO~2peak~ and CR exercise sessions on post-HTx VO~2peak~ remained after adjustment for demographic influencers of exercise capacity (age and sex) as shown in Model 1, and adjustment for demographic and clinical influencers of exercise capacity (age, sex, BMI, history of diabetes, hemoglobin, peak HR, and HR recovery (HRR)) as shown in Model 2 ([Table 4](#jcm-08-00119-t004){ref-type="table"}).

All significant univariate predictors were included into the multivariate regression analysis with adjustment for age and sex. This analysis (as shown in Model 3) indicated that CR exercise sessions and pre-HTx VO~2peak~ were the independent predictors of higher post-HTx VO~2peak~ ([Table 4](#jcm-08-00119-t004){ref-type="table"}). When CR exercise session attendance was divided into two groups by the median attendance of 18 sessions, those who attended ≥18 sessions had significantly higher post-HTx VO~2peak~ compared to those with \<18 sessions attended (≥18 sessions: 18.8 ± 4.8 vs. \<18 sessions: 16.4 ± 4.3, *p* \< 0.01) ([Figure 3](#jcm-08-00119-f003){ref-type="fig"}). The value of 18 sessions was also determined to be an appropriate cutoff for CR attendance necessary to maximize benefits in post-HTx VO~2peak~ (AUC: 0.692, specificity: 0.549, sensitivity: 0.684, *p* \< 0.001).

4. Discussion {#sec4-jcm-08-00119}
=============

The purpose of this study was to determine whether pre-HTx clinical characteristics and/or postoperative participation in CR provide utility in predicting VO~2peak~ following HTx. Pre-HTx VO~2peak~ and the number of CR exercise sessions attended were the only variables predictive of greater VO~2peak~ following HTx. These metrics independently predicted higher post-HTx VO~2peak~ even after adjusting for other factors of exercise capacity, surpassing other significant univariate factors. Our data provide new evidence of the critical benefits of CR in improving functional capacity following HTx.

Previous work has evaluated potential predictors of VO~2peak~ in various populations \[[@B10-jcm-08-00119],[@B11-jcm-08-00119],[@B12-jcm-08-00119],[@B13-jcm-08-00119],[@B14-jcm-08-00119],[@B17-jcm-08-00119],[@B18-jcm-08-00119],[@B28-jcm-08-00119],[@B29-jcm-08-00119]\]. In healthy subjects the general characteristics of younger age, male sex, and training state have been shown to be associated with improved exercise capacity \[[@B17-jcm-08-00119]\]. For those with cardiovascular disease (CVD), several studies measuring exercise capacity directly by VO~2peak~ or indirectly using predicted METS have shown overall that age and baseline fitness are the strongest predictors of VO~2peak~ \[[@B10-jcm-08-00119],[@B28-jcm-08-00119],[@B29-jcm-08-00119]\]. The predictive quality of age also remains in the HTx population \[[@B11-jcm-08-00119],[@B13-jcm-08-00119],[@B14-jcm-08-00119]\]. One of the first studies to evaluate predictors of VO~2peak~ specifically for HTx patients found that chronotropic reserve, donor age, recipient age, and time from HTx were the most significant predictors of VO~2peak~ post-HTx \[[@B11-jcm-08-00119]\]. This study, however, collected CPET data in the broad range of 1--100 months following HTx, which limits the specificity of temporal cardiopulmonary adaptation post-HTx. Although not significant in multivariate analysis, clinical history of diabetes and dyslipidemia were significant univariate predictors in this study, emphasizing the importance of multimorbidity management \[[@B30-jcm-08-00119],[@B31-jcm-08-00119],[@B32-jcm-08-00119],[@B33-jcm-08-00119]\]. More recent studies in HTx patients have shown that the demographic components of sex, BMI, and age are prominent predictors of VO~2peak~ \[[@B13-jcm-08-00119],[@B14-jcm-08-00119],[@B18-jcm-08-00119]\]. [Table 5](#jcm-08-00119-t005){ref-type="table"} provides information on four specific studies particularly relevant to the findings of the current study examining predictors of VO~2peak~ in HTx patients.

Although the findings of these studies concur with our study regarding the predictive quality of BMI, CR exercise session attendance and baseline fitness as assessed by pre-HTx VO~2peak~ were the only independent predictors of post-HTx VO~2peak~. Baseline fitness levels have previously been shown to predict VO~2peak~ in CVD patients \[[@B28-jcm-08-00119],[@B29-jcm-08-00119]\], yet this study is the first to show this relationship in HTx patients. A significant correlation was present between pre-HTx VO~2peak~ and post-HTx VO~2peak~ in our study, as those with the highest pre-HTx VO~2peak~ were more likely to have higher VO~2peak~ measurements following HTx. These results highlight the importance of maintaining or reaching a higher functional capacity leading up to HTx, as baseline values predict postoperative VO~2peak~ levels.

The predictive impact of CR involvement following HTx on achieving higher VO~2peak~ values was a unique component to this study. Our findings clearly demonstrate the importance of postoperative CR participation in improving functional capacity and implications of survival following HTx. Specifically following HTx, the benefits of CR involvement are widespread for this clinically unique population; including counteracting marked deconditioning and skeletal muscle weakness associated with end-stage HF, corticosteroid treatment, and surgical recovery \[[@B18-jcm-08-00119],[@B34-jcm-08-00119],[@B35-jcm-08-00119],[@B36-jcm-08-00119]\]. Although the predictive quality of CR session attendance has not been previously reported, the increase in VO~2peak~ following CR in HTx patients is well-documented \[[@B15-jcm-08-00119],[@B19-jcm-08-00119],[@B20-jcm-08-00119],[@B37-jcm-08-00119],[@B38-jcm-08-00119]\]. The importance of CR involvement on VO~2peak~ following HTx is critical, as it elicits significantly greater increases in VO~2peak~ compared to at-home therapy \[[@B37-jcm-08-00119]\]. One such study reported an increase of 3.6 mL/kg/min in VO~2peak~ following a 12-week CR program after HTx \[[@B19-jcm-08-00119]\]. Additionally, a recent review evaluating CR exercise in HTx patients that encompassed 10 randomized controlled trials with a total of 300 patients found that exercise capacity was, on average, 2.49 mL/kg/min higher for those who exercised \[[@B15-jcm-08-00119]\]. Our study showed a mean increase of 4.6 mL/kg/min (equivalent to over 1.5 METS) from pre- to post-HTx, which has substantial meaning with regard to improved quality of life and survival. Further, those who attended \>18 sessions demonstrated a post-HTx VO~2peak~ of 2.4 mL/kg/min higher than those who attended \<18 sessions (i.e., 15% greater). Studies in HF have found that an increased VO~2peak~ is associated with better outcomes (i.e., primary endpoints of all-cause hospitalizations and/or mortality) \[[@B6-jcm-08-00119],[@B7-jcm-08-00119],[@B39-jcm-08-00119],[@B40-jcm-08-00119]\]. One such study found a 5% lower risk of all-cause mortality or hospitalization for every 6% increase in VO~2peak~, thereby highlighting the importance of even seemingly small improvements in VO~2peak~ on long-term clinical outcomes \[[@B7-jcm-08-00119]\]. It should be noted, however, that despite significant functional improvements observed following HTx, VO~2peak~ values still remain abnormal in HTx patients compared to age-matched control subjects \[[@B34-jcm-08-00119],[@B41-jcm-08-00119],[@B42-jcm-08-00119]\]. Further understanding of the demographic, clinical, and rehabilitative components that predict post-HTx VO~2peak~ values offers greater insight into the complex cardiopulmonary and peripheral adaptations occurring following HTx.

It is important to recognize the retrospective observational nature of the present study design. Additional research in this area is encouraged to confirm these results in a prospective fashion. The distribution of post-HTx medications could potentially influence CPET measurements, therefore this should be taken into account as a limitation to the application of these results. Further, data pertaining to donor information (e.g., donor age, donor sex) and surgical procedural notes (e.g., cold ischemic time) were unavailable for this study and may be important additional metrics to include in follow-up studies.

5. Conclusions {#sec5-jcm-08-00119}
==============

In summary, HTx patients demonstrated substantial improvements in VO~2peak~ following HTx. The only factors that provided significant predictive value of higher post-HTx VO~2peak~ values were CR exercise session attendance and pre-HTx VO~2peak~, even after adjustment for other univariate predictors of post-HTx exercise capacity. These data demonstrate the influential role of sustaining and/or improving cardiorespiratory fitness leading up to and following HTx, specifically in the CR setting.
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![Flowchart for patient inclusion and exclusion. Of the initially identified 204 HTx patients, 54 patients lacked a pre-HTx or post-HTx CPET, 2 patients had incomplete CPET data, and 8 patients were lacking CR exercise session data, resulting in 140 patients for study analysis. HTx, cardiac transplantation; CPET, cardiopulmonary exercise testing.](jcm-08-00119-g001){#jcm-08-00119-f001}

![Relationship between measurements of relative VO~2peak~ from pre-HTx to post-HTx. A significant positive correlation was present between pre-HTx VO~2peak~ and post-HTx VO~2peak~ (*r* = 0.47, *p* \< 0.01). Post-HTx: following cardiac transplantation; Pre-HTx: prior to cardiac transplantation; VO~2peak~: peak oxygen uptake.](jcm-08-00119-g002){#jcm-08-00119-f002}

![Post-HTx VO~2peak~ based on median CR exercise session attendance. Those HTx patients who attended ≥18 CR exercise sessions had significantly higher post-HTx VO~2peak~ compared to those with \<18 CR exercise sessions attended (≥18 sessions: 18.8 ± 4.8 vs. \<18 sessions: 16.4 ± 4.3, *p* \< 0.01) \*, significantly higher than \<18 CR sessions. CR: cardiac rehabilitation; Post-HTx: following cardiac transplantation; VO~2peak~: peak oxygen uptake.](jcm-08-00119-g003){#jcm-08-00119-f003}

jcm-08-00119-t001_Table 1

###### 

Recipient demographics and clinical characteristics.

  *n*                                140
  ---------------------------------- ------------
  Age (years)                        52 ± 12
  Sex (Female)                       41 (29)
  Height (cm)                        172 ± 14
  Weight (kg)                        83 ± 19
  BSA (m^2^)                         2.0 ± 0.2
  BMI (kg/m^2^)                      27.1 ± 4.6
  History of Diabetes                31 (22.1)
  History of Smoking                 52 (37.1)
  History of Dyslipidemia            74 (52.9)
  History of Hypertension            63 (45)
  Previous LVAD                      27 (19.3)
  Indication for Heart Transplant    
  Restrictive Cardiomyopathy         29 (20.7)
  Dilated Cardiomyopathy             53 (37.9)
  Hypertrophic Cardiomyopathy        8 (5.6)
  Ischemic Cardiomyopathy            25 (17.9)
  Other                              25 (17.9)
  Labs                               
  Hemoglobin (g/dL)                  12.0 ± 2.0
  Hematocrit (%)                     36 ± 6
  White Blood Cell Count (10^9^/L)   7.5 ± 3.0
  Creatinine (mg/dL)                 1.4 ± 1.0
  Medications \*                     
  ACE Inhibitor                      52 (37.1)
  Amiodarone                         12 (8.6)
  Aspirin                            65 (46.4)
  Beta Blocker                       103 (73.6)
  Calcium Channel Blocker            3 (2.1)
  Diuretic                           92 (65.7)
  Number of CR Exercise Sessions     18 ± 9

Note: BMI, body mass index; BSA, body surface area; CR, cardiac rehabilitation; LVAD, left ventricular assist device. All data are presented as mean ± standard deviation or frequency (percentage). \*, medication distributions are prior to cardiac transplantation procedure; ACE, angiotensin converting enzyme.

jcm-08-00119-t002_Table 2

###### 

Peak exercise testing values prior to and following cardiac transplantation.

                                   Pre-HTx       Post-HTx      *p*-Value
  -------------------------------- ------------- ------------- -----------
  *n*                              140           140           
  Exercise time (min)              5.3 ± 1.7     6.7 ± 1.7     \<0.001
  METS                             4.9 ± 1.8     6.4 ± 1.8     \<0.001
  Absolute VO~2peak~ (L/min)       1.1 ± 0.4     1.4 ± 0.4     \<0.001
  VO~2peak~ % Predicted (%)        42 ± 14       58 ± 17       \<0.001
  Relative VO~2peak~ (mL/kg/min)   12.9 ± 4.4    17.5 ± 4.7    \<0.001
  V~E~/VCO~2~ slope                42 ± 12       37 ± 6        \<0.001
  VCO~2~ (L/min)                   1.2 ± 0.5     1.7 ± 0.5     \<0.001
  RER                              1.15 ± 0.13   1.21 ± 0.12   \<0.001
  SBP (mmHg)                       105 ± 25      145 ± 30      \<0.001
  DBP (mmHg)                       60 ± 10       67 ± 11       \<0.001
  HR (bpm)                         110 ± 21      125 ± 20      \<0.001

METS, metabolic equivalents; RER, respiratory exchange ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; VCO~2~, production of carbon dioxide; V~E~, minute ventilation; V~E~/VCO~2~ slope, ventilatory efficiency; VO~2peak~, peak oxygen uptake.

jcm-08-00119-t003_Table 3

###### 

Univariate regression analysis for predictors of VO~2peak~.

  Variable                           Univariate Analysis                  
  ---------------------------------- --------------------- -------------- ---------
  Age (years)                        0.978                 0.949--1.009   0.170
  Sex (female)                       0.457                 0.173--1.209   0.115
  BMI (kg/m^2^)                      0.896                 0.815--0.985   0.022
  History of Diabetes                0.174                 0.039--0.772   0.021
  History of Smoking                 0.805                 0.354--1.831   0.605
  History of Hypertension            0.741                 0.335--1.641   0.460
  History of Dyslipidemia            0.415                 0.185--0.929   0.032
  History of LVAD                    1.171                 0.446--3.076   0.748
  Beta Blocker Medication            0.642                 0.275--1.499   0.306
  Indication for HTx                                                      
  Restrictive Cardiomyopathy         0.812                 0.299--2.201   0.682
  Dilated Cardiomyopathy             0.920                 0.409--2.066   0.840
  Hypertrophic Cardiomyopathy        2.040                 0.461--9.035   0.348
  Ischemic Cardiomyopathy            0.565                 0.179--1.782   0.330
  Other                              1.694                 0.655--4.380   0.277
  Labs                                                                    
  Hemoglobin (g/dL)                  1.294                 1.041--1.608   0.020
  Hematocrit (%)                     1.063                 0.985--1.146   0.115
  White Blood Cell Count (10^9^/L)   0.806                 0.662--0.982   0.033
  Creatinine (mg/dL)                 0.402                 0.155--1.039   0.060
  Pre-HTx CPET Data                                                       
  Peak SBP (mmHg)                    0.998                 0.971--1.005   0.158
  Heart Rate Recovery (bpm)          1.021                 0.987--1.056   0.225
  Relative VO~2peak~ (mL/kg/min)     1.174                 1.070--1.289   0.001
  CR Exercise Sessions               1.095                 1.041--1.152   \<0.001

OR, odds ratio; CI, confidence interval; BMI, body mass index; CR, cardiac rehabilitation; HTx, cardiac transplantation; LVAD, left ventricular assist device; SBP, systolic blood pressure, VO~2peak~, peak oxygen uptake.

jcm-08-00119-t004_Table 4

###### 

Adjusted and multivariate regression analysis for predictors of Post-HTx VO~2peak~.

  Variable                           Model 1   Model 2        Model 3                                                           
  ---------------------------------- --------- -------------- --------- ------- --------------- ------- ------- --------------- -------
  Age (years)                        0.968     0.932--1.006   0.094     0.970   0.933--1.009    0.130   0.962   0.922--1.004    0.077
  Sex (female)                       0.395     0.128--1.217   0.106     0.284   0.080--1.010    0.052   0.292   0.087--0.986    0.047
  BMI (kg/m^2^)                                                         0.889   0.791--0.999    0.049   0.097   0.811--1.018    0.097
  History of Diabetes                                                   3.050   0.602--15.450   0.178   2.760   0.635--11.995   0.176
  History of Dyslipidemia                                                                               0.880   0.315--2.465    0.807
  Labs                                                                                                                          
  Hemoglobin (g/dL)                                                     1.172   0.930--1.478    0.178   1.045   0.829--1.31     0.710
  White Blood Cell Count (10^9^/L)                                                                      0.796   0.620--1.021    0.072
  Pre-HTx CPET Data                                                                                                             
  Relative VO~2peak~ (mL/kg/min)     1.145     1.037--1.264   0.007     1.110   1.002--1.231    0.047   1.206   1.068--1.361    0.002
  Peak HR (bpm)                                                         0.979   0.951--1.007    0.147                           
  HRR (bpm)                                                             1.008   0.959--1.059    0.764                           
  CR Exercise Sessions               1.102     1.037--1.264   \<0.001   1.095   1.037--1.157    0.001   1.103   1.042--1.167    0.001

OR, odds ratio; CI, confidence interval; BMI, body mass index; CPET, cardiopulmonary exercise testing; CR, cardiac rehabilitation; HR, heart rate; HRR, heart rate recovery; LVAD, left ventricular assist device; SBP, systolic blood pressure; VO~2peak~, peak oxygen uptake. Model 1: Adjustment for age and sex. Model 2: Adjustment for age, sex, and influencers of exercise capacity (body mass index, history of diabetes, hemoglobin, peak HR, and HRR). Model 3: Significant univariate predictors in multivariate analysis with adjustment for age and sex.
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Predictors of VO~2peak~ in heart transplant patients.

  Study Group                                    *n*   Age (yrs)   Predictors of VO~2peak~                                                         Time from Transplant   Post-Transplant VO~2peak~ (mL/kg/min)
  ---------------------------------------------- ----- ----------- ------------------------------------------------------------------------------- ---------------------- ------------------------------------------
  Douard et al. 1997 \[[@B11-jcm-08-00119]\]     85    52 ± 12     Chronotropic reserve, time from transplantation, age of donor, age of patient   1--100 months          21.1 ± 6.0
  Leung et al. 2003 \[[@B13-jcm-08-00119]\]      95    48 ± 14     Age, sex, height, and weight (alternatively, body mass index)                   12 months              19.9 ± 4.8
  Nytrøen et al. 2012 \[[@B18-jcm-08-00119]\]    51    52 ± 16     Muscular exercise capacity and body fat                                         1--8 years             Group 1: 23.1 ± 3.7; Group 2: 32.6 ± 4.4
  Carvalho et al. 2015 \[[@B14-jcm-08-00119]\]   60    48 ± 15     Age, sex, body mass index, heart rate reserve, and left atrium diameter         64 ± 54 months         unspecified

Note: VO~2peak~, peak oxygen uptake; yrs, years. All data are presented as mean ± standard deviation unless otherwise specified.
